---
title: 'Clinical Daily Summary: What Happened on November 17, 2026'
headline: Safusidenib showed sustained activity in a 27-person glioma study
description: Rein shared preliminary, blinded week-12 lung-function and safety findings
  for its inhaled IPF drug.
url: https://thebench.bio/news/clinical/2026-11-17
topic: clinical
date: '2026-11-17'
covers:
- '2026-11-17'
date_published: '2026-11-17T12:02:34Z'
date_modified: '2026-11-17T12:02:34Z'
tags:
- Clinical
sources: 2
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on November 17, 2026

**Safusidenib showed sustained activity in a 27-person glioma study**

Rein shared preliminary, blinded week-12 lung-function and safety findings for its inhaled IPF drug.

## Today in brief

In 27 people with grade 2 IDH1-mutant glioma, safusidenib had an 81.5% confirmed clinical benefit rate, with median drug exposure of 46.7 months. [1] Rein reported preliminary week-12 findings from its ongoing Phase II trial of inhaled LTI-03, with no serious treatment-emergent adverse events in the initial blinded review. [2]

## Also worth knowing

- Central review in Nuvation Bio’s Phase II J201 study found a 51.9% confirmed objective response rate. Adverse events led three patients to stop treatment, and the company is advancing a Phase III study. [1]
- Of 24 evaluable participants in Rein’s initial blinded review, eight had improved forced vital capacity at week 12, while 11 had a decline of no more than 5.7%. The company expects unblinded top-line results in 2027. [2]

## The day in numbers

- **81.5%**: Confirmed clinical benefit rate in Nuvation Bio’s Phase II J201 study of safusidenib, based on central review. [1]
- **46.7 months**: Median safusidenib exposure in the long-term Phase II update. [1]
- **24 participants**: Number evaluable in Rein’s initial blinded review of LTI-03. [2]

## Sources

1. [Nuvation Bio reports updated Phase II J201 data for safusidenib](<https://www.clinicaltrialsarena.com/news/nuvation-updated-j201-data-safusidenib/>), Clinical Trials Arena, 2026-11-17
2. [Rein reports early Phase II data for inhaled IPF drug](<https://www.clinicaltrialsarena.com/news/rein-phase-data-ipf-drug/>), Clinical Trials Arena, 2026-11-17

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.clinicaltrialsarena.com/news/nuvation-updated-j201-data-safusidenib/>
[2]: <https://www.clinicaltrialsarena.com/news/rein-phase-data-ipf-drug/>
